Identifying patients with type 2 diabetes at high risk of microalbuminuria : results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study
Rossi, Maria C. E., Nicolucci, Antonio, Pellegrini, Fabio, Comaschi, Marco, Ceriello, Antonio, Cucinotta, Domenico, Giorda, Carlo, Valentini, Umberto, Vespasiani, Giacomo and De Cosmo, Salvatore. (2008) Identifying patients with type 2 diabetes at high risk of microalbuminuria : results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. Nephrology, Dialysis, Transplantation, Volume 23 (Number 4). pp. 1278-1284. ISSN 0931-0509Full text not available from this repository.
Official URL: http://dx.doi.org/10.1093/ndt/gfm798
Background. We evaluated to what extent the presence of risk factors and their interactions increased the likelihood of microalbuminuria (MAU) among individuals with type 2 diabetes. Methods. Fifty-five Italian diabetes outpatient clinics enrolled a sample of patients with type 2 diabetes, without urinary infections and overt diabetic nephropathy. A morning spot urine sample was collected to centrally determine the urinary albumincreatinine ratio (ACR). A tree-based regression technique (RECPAM) and multivariate analyses were performed to investigate interaction between correlates of MAU. Results. Of the 1841 patients recruited, 228 (12.4%) were excluded due to the presence of urinary infections and 56 (3.5) for the presence of macroalbuminuria. Overall, the prevalence of MAU (ACR 30-299 mg/g) was of 19.1%. The RECPAM algorithm led to the identification of seven classes showing a marked difference in the likelihood of MAU. Non-smoker patients with HbA1c < 7% and waist circumference <= 102 cm showed the lowest prevalence of MAU (7.5%), and represented the reference class. Patients with retinopathy, waist circumference > 98 cm and HbA1c > 8% showed the highest likelihood of MAU (odds ratio 13.7; 95% confidence intervals 6.8-27.6). In the other classes identified, the risk of MAU ranged between 3 and 5. Age, systolic blood pressure, HDL cholesterol levels and diabetes treatment represented additional, global correlates of MAU. Conclusions. The likelihood of MAU is strongly related to the interaction between diabetes severity, smoking habits and several components of the metabolic syndrome. In particular, abdominal obesity, elevated blood pressure levels and low HDL cholesterol levels substantially increase the risk of MAU. It is of primary importance to monitor MAU in high-risk individuals and aggressively intervene on modifiable risk factors.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Library of Congress Subject Headings (LCSH):||Cardiovascular system -- Diseases -- Prevention, Cardiovascular system -- Diseases -- Risk factors, Albuminuria, Recursive partitioning -- Computer programs, Survival analysis (Biometry) -- Computer programs, Non-insulin-dependent diabetes -- Complications, Diabetic angiopathies|
|Journal or Publication Title:||Nephrology, Dialysis, Transplantation|
|Publisher:||Oxford University Press|
|Number of Pages:||7|
|Page Range:||pp. 1278-1284|
|Access rights to Published version:||Restricted or Subscription Access|
|Funder:||Sanofi Aventis (Firm)|
|References:||1. Haffner SM, Lehto S,RonnemaaTet al.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234 2. Molitch ME, DeFronzo RA, Franz MJ et al. American Diabetes Association: nephropathy in diabetes. Diabetes Care 2004; 27 (Suppl 1): S79–S83 3. Tobe SW,McFarlane PA, Naimark DM. Microalbuminuria in diabetes mellitus. CMAJ 2002; 167: 499–503 4. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413–1418 5. Ochodnicky P, Henning RH, van Dokkum RP et al.Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006; 47 (Suppl 2): S151–S162 6. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74. Diabetes 2006; 55: 1832–1839 7. Grundy SM, Brewer HB, Cleeman JI et al. for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433–438 8. The IDF consensusworldwide definition on the Metabolic Syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf (p. 13) 9. Naushahi MJ, de Grauw WJ, Avery AJ et al. Risk factors for development of impaired renal function in type 2 diabetes mellitus patients in primary care. Diabet Med 2004; 21: 1096–1101 10. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Geneva: World Health Organization, 1999 11. Clinical guidelines task force. Global guidelines for type 2 diabetes. International Diabetes Federation, 2005. http://www.idf.org/webdata/ docs/IDF%20GGT2D.pdf (p. 56) 12. Grundy SM, Cleeman JI, Bairey Merz CN et al. For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education ProgramAdult Treatment Panel III Guidelines. Circulation 2004; 110: 227–239 13. Nicolucci A, Carinci F, Ciampi A. Stratifying patients at risk of diabetic complications: an integrated look at clinical, socioeconomic, and care-related factors. SID-AMD Italian Study Group for the Implementation of the St. Vincent Declaration. Diabetes Care 1998; 21: 1439–1444 14. Ciampi A. Constructing prediction trees from data: the RECPAM approach. Proceedings from the Prague 1991 Summer School on Computational Aspects of Model Choice. Heidelberg: Physica-Verlag, 1992, 105–152 15. Dixon AN, Raymond NT, Mughal S et al. Prevalence of microalbuminuria and hypertension in South Asians and white Europeans with type 2 diabetes: a report from the United Kingdom Asian Diabetes Study (UKADS). Diab Vasc Dis Res 2006; 3: 22–25 16. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11–25 17. Parving HH, Lewis JB, RavidMet al.DEMANDInvestigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057– 2063 18. de Boer IH, Sibley SD, Kestenbaum B et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group.Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007; 18(1): 235–243 19. Chandie Shaw PK, Berger SP, Mallat M et al. Central obesity is an independent risk factor for albuminuria in nondiabetic South Asian Subjects. Diabetes Care Jul 2007; 30(7): 1840–1844 20. Molitch ME, Rupp D, Carnethon M. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care 2006; 29: 78–82 21. Smulders YM, Rakic M, Stehouwer CD et al. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study. Diabetes Care 1997; 20: 999–1005 22. Gaede P, Parving HH, Pedersen O. Long-termeffects of intensive multifactorial treatment on total and cardiovascular mortality in patients with type 2 diabetes. Diabetologia 2007; 50 (Suppl 1): S4 23. Gansevoort RT, Verhave JC, Hillege HL et al. for the PREVEND Study Group. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int 2005; 94 (Suppl): S28–S35|
Actions (login required)